Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

Bear Stearns Keeps 'Outperform' on OSI Pharma


Bear Stearns reiterates outperform on OSI Pharmaceuticals (OSIP).

Analyst Akhtar Samad says that on Monday, OSI received fast track status with the FDA for its Tarceva drug in refractory non-small cell lung cancer. Samad says OSI now plans to expand its Tarceva Phase III lung cancer trial, and downsize its Tarceva Phase III pancreatic cancer trial. He views this move as positive as he believes that Tarceva's pancreatic cancer trial poses a higher risk. He thinks the move also will allow OSI to focus on its refractory lung cancer indication.

Samad continues to view the Tarceva refractory lung trial as better designed. He maintains a roughly $20 target, based on shares trading at a multiple of 40 times his $1.59 2007 earnings per share estimate.


The Aging of Abercrombie & Fitch
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus